Consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 605,220	$ 509,338	$ 537,840
Cost of revenues	137,181	128,280	114,867
Gross profit	468,039	381,058	422,973
Operating costs and expenses:
Research, development and clinical studies	209,645	223,062	206,085
Sales and marketing	239,063	226,809	173,658
General and administrative	189,827	164,057	132,753
Total operating costs and expenses	638,535	613,928	512,496
Operating income (loss)	(170,496)	(232,870)	(89,523)
Financial (expenses) income, net	39,334	41,130	7,677
Total income (loss) before income taxes	(131,162)	(191,740)	(81,846)
Income tax	37,465	15,303	10,688
Net income (loss)	$ (168,627)	$ (207,043)	$ (92,534)
Basic net income (loss) per ordinary share (in usd per share)	$ (1.56)	$ (1.95)	$ (0.88)
Diluted net income (loss) per ordinary share (in usd per share)	$ (1.56)	$ (1.95)	$ (0.88)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	107,834,368	106,391,178	104,660,476
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	107,834,368	106,391,178	104,660,476